As demonstrated through immunohistochemistry, the positive expression of the KRAS oncoprotein in the cytoplasm of tumor cells was relatively weak in the tumors derived from the RC‐ODC/AZ group (Fig. 4c). The gene discussed is KRAS; the disease is neoplasm.